WC
FENC icon

Wexford Capital’s Fennec Pharmaceuticals FENC Stock Holding History

Wexford Capital’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-26,414
Closed -$161K – 273
2025
Q1 		$161K Hold
26,414
– – 0.04% 189
2024
Q4 		$167K Hold
26,414
– – 0.03% 173
2024
Q3 		$132K Hold
26,414
– – 0.03% 159
2024
Q2 		$161K Hold
26,414
– – 0.04% 179
2024
Q1 		$294K Hold
26,414
– – 0.06% 176
2023
Q4 		$296K Hold
26,414
– – 0.06% 132
2023
Q3 		$198K Hold
26,414
– – 0.04% 180
2023
Q2 		$233K Buy
+26,414
New +$220K 0.05% 170

Other funds holding FENC

SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HFA
Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wexford Capital's FENC Position: Q2 2025 in Review

Wexford Capital sold out of Fennec Pharmaceuticals (FENC) in Q2 2025, closing a stake of 26,414 shares — an estimated $161K sold.

Wexford Capital first reported a position in FENC in Q2 2023 and held it in 8 quarters. The position peaked at $296K in Q4 2023. 78 funds tracked by Wall St. Rank hold FENC as of Q2 2025.

  • Wexford Capital reported no remaining Fennec Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Wexford Capital sold 26,414 Fennec Pharmaceuticals shares in Q2 2025, an estimated $161K.
  • Wexford Capital first reported a position in Fennec Pharmaceuticals in Q2 2023 and held it in 8 quarters.
  • Wexford Capital's Fennec Pharmaceuticals position peaked at $296K in Q4 2023.
  • 78 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q2 2025.

Based on Wexford Capital's 13F filing for Q2 2025, filed 14 Aug 2025.